Thursday, July 30, 2020

Onconova Therapeutics Inc. (ONTX)

Preliminary Data Is Expected In Q3 2020 Following Required Number Of Survival Events Reached

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.

Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Required number of survival events reached in the INSPIRE trial.  Yesterday, Onconova announced that the required number of survival events has been reached for the pivotal Phase 3 INSPIRE trial data analysis. The company plans to provide preliminary top-line data in Q3 2020 and full top-line data at a medical conference in Q4 2020 -potentially at the Annual American Society of Hematology (ASH) meeting in December 2020.

What does this mean for the company? Based on this news, the company’s guidance of INSPIRE data is on track to read out in H2 2020. The median survival rate of high-risk MDS patients who failed azacytidine treatment is 5.6 months. The primary endpoint assessment was set to start dependent on this targetted survival event ...

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report.  NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.